NCT01874431View on ClinicalTrials.gov

Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy

PHASE2CompletedINTERVENTIONAL
Enrollment

823

Participants

Timeline

Start Date

June 12, 2013

Primary Completion Date

July 9, 2014

Study Completion Date

August 7, 2014

Conditions
Diabetic Nephropathies
Interventions
DRUG

Finerenone (BAY94-8862)

DRUG

Placebo

Trial Locations (147)

110

Taipei

833

Kaohsiung City

1085

Budapest

1130

Vienna

1431

Sofia

1739

Krugersdorp

1812

Klipsruit West

1829

Lenasia South

2065

St Leonards

2113

Newtown

2326

Hamar

2730

Herlev

2820

Gentofte Municipality

3052

Melbourne

3073

Reservoir

3086

Graz

3100

Sankt Pölten

3128

Box Hill

3168

Clayton

3181

Prahran

3300

Eger

4002

Plovdiv

4032

Debrecen

4037

Durban

4052

Merebank

4067

Durban

4091

Durban

4102

Woolloongabba

4300

Holbæk

4400

Tongaat

5020

Salzburg

5026

Salzburg

5770

Lukovit

6000

Stara Zagora

Kolding

6020

Innsbruck

6026

Ålesund

6300

Haskovo

6850

Worcester

7003

Rousse

7130

Somerset West

7460

Goodwood

7570

Cape Town

8000

Aarhus C

8500

Pápa

8800

Nagykanizsa

9000

Varna

9010

Varna

10002

Taipei

11217

Taipei

11355

Flushing

11407

Jerez de la Frontera

12808

Prague

15405

Ferrol

17007

Girona

20134

Milan

20157

Milan

20520

Turku

20832

Monza-Brianza

24020

Bergamo

24127

Bergamo

28034

Madrid

28041

Madrid

29118

Orangeburg

29185

Kristianstad

30625

Hanover

32545

Bad Oeynhausen

33015

Miami

33028

Pembroke Pines

33520

Tampere

35128

Padua

35294

Birmingham

37408

Chattanooga

38700

La Tronche

40210

Düsseldorf

40620

Jyväskylä

46520

Sagunto

48504

Flint

49241

Busan

56124

Pisa

56564

Neuwied

60611

Chicago

60612

Chicago

67059

Ludwigshafen am Rhein

67091

Strasbourg

69437

Lyon

71013

Foggia

75908

Paris

80000

Amiens

80131

Napoli

90022

Los Angeles

90100

Oulu

91910

Chula Vista

95032

Los Gatos

4428164

Kfar Saba

4941492

Petah Tikva

5822012

Holon

6203854

Tel Aviv

6937947

Tel Aviv

7830604

Ashkelon

9112001

Jerusalem

06510

New Haven

75235-3858

Dallas

05401

Burlington

V5Z 1L8

Vancouver

V6E 1M7

Vancouver

L1E 3C3

Courtice

N2H 5Z8

Kitchener

M1H 3G4

Scarborough Village

M4C 5T2

Toronto

M4N 3M5

Toronto

H1T 2M4

Montreal

537 01

Chrudim

742 21

Kopřivnice

794 01

Krnov

DK-3400

Hillerød

DK-7500

Holstebro

00180

Helsinki

Unknown

Hong Kong

Shatin

Warsaw

09134

Cagliari

1311 RL

Almere Stad

5600 PD

Eindhoven

9713 GZ

Groningen

7909 AA

Hoogeveen

6229 HX

Maastricht

15-276

Bialystok

85-822

Bydgoszcz

90-153

Lodz

20-081

Lublin

55-200

Oława

51-162

Wroclaw

2801-951

Almada

1069-166

Lisbon

1449-005

Lisbon

03722

Seoul

06591

Seoul

08025

Barcelona

651 85

Karlstad

701 85

Örebro

541 85

Skövde

111 57

Stockholm

113 24

Stockholm

141 86

Stockholm

753 19

Uppsala

162 68

Vällingby

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT01874431 - Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy | Biotech Hunter | Biotech Hunter